During Trastuzumab Therapy, Many Patients May Have Suboptimal Cardiac Monitoring
the Cancer Therapy Advisor take:
A large proportion of patients treated with adjuvant trastuzumab had suboptimal cardiac monitoring, a recent study published in the Journal of Clinical Oncology has shown.
For the study, researchers sought to investigate the patterns of cardiac monitoring and identify factors associated with adequate monitoring among older patients with breast cancer treated with adjuvant trastuzumab. Researchers identified 2,203 patients with a median age of 72 years will full Medicare coverage, diagnosed with stage I-III breast cancer, and treated with trastuzumab-based chemotherapy.
Results showed that only 36.0% of patients were adequately monitored for cardiac toxicity. Researchers found that a more recent year of diagnosis (HR = 1.83; 95% CI: 1.32-2.54), anthracycline use (HR = 1.39; 95% CI: 1.14-1.71), female prescribing physician (HR = 1.37; 95% CI: 1.10-1.70, and physician graduating after 1990 (HR = 1.66; 95% CI: 1.29-2.12) were associated with optimal cardiac monitoring.
The findings suggest that efforts to improve the adequacy of cardiac monitoring during adjuvant trastuzumab treatment are needed, especially in patients at higher risk for cardiotoxicity.
A large proportion of breast cancer patients treated with adjuvant trastuzumab had suboptimal cardiac monitoring.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer